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ct would seem, at first blush, that we should have the
revention of heart disease well in hand. Simply put, there
s ample evidence to support the positive impact of aggres-
ive risk factor management in reducing cardiovascular
vents, improving quality of life, and facilitating long-term
urvival. Tools such as the upcoming 2005 American
ollege of Cardiology/American Heart Association (ACC/
HA) Guideline Update of the ACC/AHA Secondary
revention for Patients With Coronary and Other Athero-
clerotic Vascular Disease provide excellent reviews of the
ifestyle changes and pharmacologic therapies that should be
mployed in individuals with established atherosclerotic
ascular disease.
Yet, despite this abundance of knowledge and clear
linical direction, we are facing an uphill battle. A growing
ercentage of the U.S. population is entering an age where
ardiovascular disease is commonplace. Rates of obesity are
n the rise, particularly—and sadly—among young children
nd adolescents. Participation in regular forms of exercise is
isappointingly low. Not surprisingly, rates of dyslipidemia,
iabetes mellitus, and metabolic syndrome also are on the
ise. As such, we predict an increased use of drug-eluting
tents, implantable cardioverter-defibrillators, and other ex-
ensive therapies that will continue to escalate costs in our
ealth care system.
HAT CAN WE DO?
s the American College of Cardiology (ACC), our ap-
roach to atherosclerotic vascular disease needs to change.
e must put a greater emphasis on attempts to prevent,
low, or ideally halt the progression of heart disease. Our
ocus should be to develop and help caregivers to implement
revention strategies for every individual at risk for cardio-
ascular disease, as well as to redefine what is meant by
revention.
Traditionally, prevention has been classified as either
rimary or secondary, based on the presence of a defining
ardiovascular event (e.g., myocardial infarction). We are
ow entering an era, however, where identification of
ubclinical atherosclerosis is a reality. Recently, Dr. David
elermajer coined the term “primary-and-a-half preven- rion” for asymptomatic individuals with no history of a
ardiac event who, on the basis of blood tests (e.g., high-
ensitivity C-reactive protein, lipids, and so on) or imaging
odalities (e.g., cardiac computed tomography, carotid
ntima media thickness), can be identified as candidates for
ore intensive preventive strategies (1). We also have data
hat exercise treadmill testing to determine exercise capacity
nd heart rate recovery may be quite useful in predicting
ortality in intermediate-risk adults (2,3).
Unfortunately, the intensity with which risk factors or
vidence of asymptomatic disease in such individuals should
e treated remains unknown. How low should their blood
ressure be? To what level should their low-density lipopro-
ein cholesterol (LDL-C) be reduced? As technology pro-
ides us with a better look inside our patients, we need to be
repared with answers as to how best to treat them.
One strategy is to develop cost-effective methods of
dentifying patients who are considered to be “low” or
intermediate” risk by the traditional Framingham risk score
ut who would likely benefit from additional blood tests or
maging tests to see if they might qualify for more aggressive
isk factor modification. Further, the Framingham score
ay underestimate risk in some individuals because it does
ot take into account waist circumference, triglyceride
evels, elevated fasting glucose, or family history, and it
ends to overemphasize age. Moreover, while an adult with
iabetes is classified as high risk, that same adult with a
lightly lower glucose level may not qualify for any type of
harmacologic therapy.
There are many questions to be answered: Asymptomatic
dults can now be diagnosed with moderate or advanced
oronary or carotid atherosclerosis. Should such a person be
reated to standard primary or secondary prevention goals,
r should we aim for the more aggressive “optional” LDL-C
nd non–high-density lipoprotein cholesterol (HDL-C)
argets to help arrest the progression of his or her athero-
clerosis? The National Cholesterol Education Program
uidelines termed diabetes and peripheral arterial disease as
oronary heart disease risk equivalents. Should we add
hronic kidney disease and advanced subclinical atheroscle-
osis to this list?
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President’s Page November 1, 2005:1777–8Although we may believe these conditions do warrant
ggressive secondary prevention strategies, we are not ade-
uately treating the risk factors of patients with known
oronary artery disease or diabetes, in whom the imperative
o prevent recurrent disease is clear. Patients, physicians,
nd other health care providers are not fully utilizing the
nowledge and tools available to lower cardiovascular dis-
ase (CVD) risk. A major focus of the ACC, in particular,
hould be improving guideline adherence, reducing the gap
n utilization of proven therapies, and promoting strategies
o sustain the use of risk reduction therapies in order to
ptimize cardiovascular care.
CC LEADERSHIP IN THE FIELD OF PREVENTION
n the spring of 2005, the ACC convened a task force to
evelop a background paper on the organization’s future
ole in the area of prevention. The Prevention Task Force
as charged with developing a 10-year outlook on the field
ith respect to diagnosis and treatment of asymptomatic
isease, improving adherence to guidelines, and the poten-
ial impact of emerging fields of genomics, proteomics, and
etabolomics. This task force’s recommendations build on
substantial record of involvement in setting quality stan-
ards for prevention.
Over the past decade, the ACC has substantially in-
reased prevention content in its programs and activities,
uch as in its flagship general cardiology self-primer ACC
elf-Assessment Program (SAP). For example, in 1999, the
CC/AHA/American College of Physicians (ACP) guide-
ines for the management of chronic stable angina included
he “ABC” treatment mnemonic of Aspirin and anginals,
eta-blocker and blood pressure, Cholesterol and cigarettes,
iet and diabetes, Education and exercise (4). A modified
ersion of the ABC approach is now the cornerstone of an
vidence-based approach to primary and secondary preven-
ion of CVD (5).
The 2005 ACC Prevention Task Force firmly holds that
e should advocate for improved reimbursement for disease
etection and prevention activities, promote multidisci-
linary teams through advocacy and education, and develop
implified guidelines on prevention. It also calls for greater
dvocacy for prevention research and the creation of training
odules on prevention for cardiovascular medicine trainees
nd other health care providers. These priorities were
dopted by the Board of Trustees at its most recent meeting.
By the end of this decade, we hope to achieve major
harmacologic advances in the areas of HDL-C–raising
rugs, smoking cessation, and weight loss medications. In
he next decade, targeted therapies based on genetic, pro-
eomic, and metabolic diagnostic testing may become a
eality. As these new technologies gradually emerge, new
ontinuing education programs and updates to existing
uidelines will be needed to deal with the knowledge gaps of
he cardiovascular specialist. Our new and expanded Car-
iosource Website is a great source of reliable clinicalnformation about emerging technologies and other ad-
ances in the area of prevention. The Prevention Commit-
ee will be expanded to include new members with expertise
n emerging technologies, vascular biology, and genetics.
The ACC plans to continue its work with other organi-
ations such as the AHA, the American Society of Hyper-
ension, and the American Diabetes Association to develop
nified guidelines for prevention that will update the recent
ollaboration between several major organizations (6). We
ill also actively work to align ourselves with organizations
nd campaigns focused on primordial prevention (promo-
ion of healthy behavioral patterns to prevent risk factor
evelopment), such as those targeting childhood obesity.
e hope to promote more widespread use of multidisci-
linary teams (nurses, nutritionists, exercise physiologists)
hrough ACC Cardiac Care Associates, as well as greater
ooperation with organizations such as the Preventive Car-
iology Nurses Association.
ALL TO ACTION
he cornerstones of a healthy heart are indisputably a
ealthy diet and regular activity. A healthy diet is one that
s low in saturated fats, trans-fatty acids, and simple sugars,
ith an increased amount of vegetables, fruit, and whole
rains. And all children, adolescents, and adults should be
ncouraged to accumulate 30 min of brisk activity most days
f the week. These simple measures, following the “ounce of
revention is worth a pound of cure” paradigm, are all we
eed to remember as we implement the ABCs of prevention
or our patients and for ourselves (5). Prevention does not
ave to be complicated, and the ACC is committed to
etting the message out to all through education, increased
upport for research and training, and partnerships with
ther organizations.
ddress correspondence to: Dr. Pamela S. Douglas, American
ollege of Cardiology, c/o Cathy Lora, 9111 Old Georgetown
oad, Bethesda, Maryland 20814-1699.
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